{"prompt": "['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', 'TABLE OF CONTENTS', 'Contents', 'SIGNATURES', '3', 'Signed:', 'Date: October 19, 2020 Dr. Marcel Bonn-Miller', '3', 'Investigator Signature.', '3', 'Signed:', 'Date: October 22, 2020 Dr. Dwight Moulin', '3', 'TABLE OF CONTENTS', '4', 'LIST OF APPENDICES', '5', 'SYNOPSIS', '6', 'ABBREVIATIONS AND DEFINITIONS OF TERMS', '13', '1. BACKGROUND INFORMATION AND STUDY RATIONALE', '14', '1.1 Background', '14', '1.2 Rationale', '14', '2.', 'STUDY OBJECTIVES AND PURPOSE', '15', '2.1 Objectives', '15', '2.1.1', 'Primary Objective', '15', '2.1.2', 'Secondary Objectives', '15', '2.1.3', 'Safety Objective', '15', '3.', 'STUDY DESIGN', '16', '3.1', 'Description of the Study', '16', '4.', 'STUDY MEDICATION', '18', '4.1 Study Medication Prescribing/Authorization', '18', '4.2 Study Medication: Cannabinoid Content Calculation', '19', '4.3 Study Medication Safety Information', '19', '5. RECRUITMENT', '20', '5.1 Site Eligibility', '20', '5.2 Investigator Training', '20', '6.', 'SUBJECT SELECTION AND WITHDRAWAL CRITERIA', '21', '6.1 Subject Inclusion Criteria', '21', '6.2 Subject Exclusion Criteria', '21', '6.3 Subject Withdrawal from Study Participation', '21', '7.', 'OUTCOME ASSESSMENTS', '22', '7.1 Study Endpoints', '22', '7.2 Study Assessments', '22', '7.2.1', 'EQ5D-5L-Euro QoL.', '22', '7.2.2', 'BPI-SF', '22', '7.2.3', 'PGI-C', '22', '7.2.4', 'CGI-I', '23', '7.2.5', 'Determination of Opioid Consumption', '23', '25 November 2020', 'CONFIDENTIAL', 'Page 4 of 79']['Protocol #710-4502', 'CANOPY GROWTH', 'CORPORATION', '7.2.6', 'Other Concomitant Medications', '23', '7.2.7', 'AEs/SAEs', '23', '7.2.7.1', 'AE Definition', '23', '7.2.7.2', 'SAE Definition', '23', '7.2.7.3', 'AE Severity', '24', '7.2.7.4', 'Relationship of AEs to Study Products', '24', '8.', 'DATA HANDLING AND RECORD KEEPING', '25', '8.1', 'Data Collection', '25', '8.2 Data Management', '25', '8.3 Data Monitoring', '25', '8.4 Record Retention', '25', '8.5 Database Access', '25', '9.', 'STATISTICAL METHODS', '27', '9.1 Statistical overview', '27', '9.2 Sample Size', '27', '9.3 Handling of Dropouts, Missing Data', '28', '9.4 Statistical Software', '28', '10. ETHICS', '29', '10.1 Ethical Conduct of the Study', '29', '10.2 Subject Information and Consent.', '29', '11. STUDY TERMINATION', '30', '12. PUBLICATION POLICY', '31', '13. REFERENCES', '32', '14. APPENDICES', '34', 'LIST OF TABLES', 'Table 1.', 'Schedule of Events', '12', 'LIST OF APPENDICES', 'Appendix 1 Physician-verified Baseline Assessment', '34', 'Appendix 2 Physician-verified Follow-up Assessment', '50', 'Appendix 3 Subject-verified Follow-up Assessment', '68', 'Appendix 4 ST Discontinuation', '76', 'Appendix 5 Exit Assessment', '78', 'Appendix 6 Classification of Chronic Pain IASP ICD 11', '79', '25 November 2020', 'CONFIDENTIAL', 'Page 5 of 79']\n\n###\n\n", "completion": "END"}